Relypsa (NASDAQ:RLYP) had an volatile session and gained 0.41 points till last call. The price was at $19.75, gaining 2.12% till the last intraday data. The total uptick value was $9.1 million while the total downtick value was $11.45 million. The shares saw a net money flow of $(-2.35) million and the up/down ratio stood at 0.79. The stock has seen a change of of -1.05% for the week. The share had a block transaction during the course of trading in which the net money flow was $(-2.06) million. Almost $0 million were received in upticks and approximately $2.06 million were lost in downticks, thereby giving the up/down ratio of 0.
Currently the company Insiders own 4.2% of Relypsa shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -34.03% . Institutional Investors own 81.43% of Relypsa shares. During last six month period, the net percent change held by insiders has seen a change of 71.72%. On the companys insider trading activities,The director of Relypsa Inc, Torley Helen sold 1,013 shares at $19.32 on June 7, 2016. The Insider selling transaction had a total value worth of $19,571. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Relypsa (NASDAQ:RLYP) : On Monday heightened volatility was witnessed in Relypsa (NASDAQ:RLYP) which led to swings in the share price. The stock opened for trading at $19.02 and hit $19.9 on the upside , eventually ending the session at $19.75, with a gain of 2.12% or 0.41 points. The heightened volatility saw the trading volume jump to 2,358,243 shares. The 52-week high of the share price is $35.97 and the company has a market cap of $884 million. The 52-week low of the share price is at $10.26 .
Many analysts have stated their opinion on the company shares. In a research note released to the investors, Wedbush maintains its rating on Relypsa (NASDAQ:RLYP).The analysts at the brokerage house have a current rating of Outperform on the shares. In a recent information released to the investors, Wedbush maintains the price target of $51 per share. The rating by the firm was issued on June 9, 2016.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Companys lead product candidate, Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration, or FDA. The Companys NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials, four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment, or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.